Science Publications & Talks

Shortcuts 2024 2023 2022 2021 2020 2018 2017 2016 2015 2013 2012 2011

2024

• THT 2024 CardiALLO HF Trial Interim Results

  THT 2024 CardiALLO HF Trial Interim Results

• THT 2024 CardiAMP HF Trial Interim Results

  THT 2024 CardiAMP HF Trial Interim Results

2023

• Article

  Altman, P. & Kalbermatten, M. (2023). Trans-endocardial delivery: The importance of the right solution. Med-Tech Innovations. June 23, 2023.

• Poster

  Johnston, PV, Bellumkonda, L, Raval, AN, et al. Cardiac Remodeling after Intramyocardial Autologous Bone Marrow Mononuclear Cell Therapy for Ischemic Cardiomyopathy: 2-Year Echocardiography Results. Presented at Annual Meeting of American College of Cardiology; March 6, 2023.

2022

• Poster

  Johnston, PV, Anderson, RD, Raval, AN, et al. Autologous Cell Therapy for HFrEF: Efficacy Outcomes at Two Years for the Roll-in Cohort of a Phase III Pivotal Trial. Presented at Annual Meeting of Heart Failure Society of America; September 30-October 3, 2022.

• Presentation

  Allogeneic NK-1R+ MSCs in Development for Acute Respiratory Distress Syndrome Secondary to COVID 19

2021

• Presentation

  Anderson RD, et al. CardiAMP Cell Therapy Trial for Heart Failure: Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with NYHA Class II & III Ischemic Systolic Heart Failure, Heart Failure Society of America Annual Conference, September 2021.

• Presentation

  Miller L, et al. Women with Heart Failure in the CardiAMP Cell Therapy Trial. Presented at Annual Meeting Heart Failure Society of America Annual Conference; September 2021.

• Presentation

  Raval A, et al. High Doses of CD34+ Cells Delivered to Patients in the CardiAMP Cell Therapy Heart Failure Trial, European Society of Cardiology Heart Failure Annual Meeting, June 2021.

2020

• Paper

  Raval, AN, Johnston, PV, Duckers, HJ, et al. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasability results from CardiAMP heart failure roll-in cohort. Int J Cardiol. 2020 Oct 20; S0167-5273(20)33996-6

• Paper

  Raval, AN, Pepine, CJ. Clinical safety profile of transendocardial catheter injection systems: A plea for uniform reporting. Cardiovasc Revasc Med 2020 Jun 30; S1553-8389(20)30416-4.

2018

• Presentation

  Johnston, PV, Duckers, HJ, Raval, AN, Cook, TD, Traverse, JH, Abraham, WT, Altman, PA, Pepine, CJ. The CardiAMPHeart Failure Trial: Efficacy Outcomes from Roll-In Phase. Presented at the Annual Scientific Sessions of the American Heart Association, November 12, 2018.

• Paper

  Johnston P, Duckers H, Raval A, Cook TD, Pepine CJ. Not all stem cells are created equal: The case for prospective assessment of stem cell potency in the CardiAMP Heart Failure Trial. Circ Res 2018;123:944–46.

• Presentation

  Duckers, HJ, Ravel AN, Pepine, CJ, Johnston, PV, Traverse JH, Emery, J, Miller, L, Abraham, WT, Altman, PA. Performance of Helix transendocardial biotherapeutic delivery system after 300 cases. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.

• Presentation

  Johnston PV, Duckers HJ, Raval AN, Cook T, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP™ Heart Failure Clinical Trial First Results from the Unblinded Roll-In Phase. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.

• Poster

  Pepine, CJ, Raval, AN, Johnston, PV, Traverse, JH, Abraham, WT, Altman, PA. CardiAMP™ Heart Failure Trial Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using CardiAMP Cell Therapy System in Patients with Post Myocardial Infarction Heart Failure. Presented at Annual Meeting of Heart Failure Society of America. September 15-18, 2018.

• Paper

  Raval AN, Cook TD, Duckers HJ, Johnston PV, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post–myocardial infarction heart failure: Trial rationale and study design, Am Heart J. 2018 Jul;201:141-148.

2017

• Paper

  Mitsutake Y, Pyum WB, Rouy D, et al. Improvement of local cell delivery using Helix Transendocardial Delivery Catheter in a porcine heart. Int Heart J. 2017.

2016

• Paper

  Bergmann MW, Heeger C, Jaquet K, Boosfeld C et al. Early Transendocardial Autologous Bone Marrow Injection Of Bone Marrow Derived Mononuclear Cells Following Ischemic Myocardial Events (the Alster - Helix Phase I Study), CRT 2016.

2015

• Poster

  Wong Po Foo, C, Rouy, D, et al. The Transendocardial Autologous Cells in Ischemc Heart Failure Trial Bone Marrow Mononuclear Cells (TAC-HFT-BMC) Randomized Placebo Controlled Blinded Study. Poster presented at: World Conference for Regenerative Medicine; 2015 Oct 21-23.

2013

• Paper

  Heldman AW,  DiFede DL,  Fishman JE et al.  Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy The TAC-HFT Randomized Trial JAMA. 2013.282909.

2012

• Paper

  Hare JM, Fishman, JE, Gerstenblith G, et al. Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy, The POSEIDON Randomized Trial, JAMA. 2012;308(22).

2011

• Paper

  de la Fuente LM, Stertzer SH, Argentieri J, et al. Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two year follow-up in an open-label phase I safety study (the TABBMI Study). Eurointervention: J of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the ESC. 2011 Nov;7(7):805-12.